spacer gif spacer gif spacer gif spacer gif ARCHIVE ANNOUNCEMENT! spacer gif
 QUICK SEARCH:   [advanced]


spacer gif
     Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents    


Right arrow Help viewing high resolution images
Right arrow Return to article
(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)

Click on image to view larger version.



Fig. 7. Dominant-negative XStau blocks VLE localization in vivo. (A) Full-length XStau (WT, above) and XStau234 (DN, below) are shown. The double-stranded RNA binding domains (dsRBDs) are shown in blue and are numbered, and the tubulin-binding domain (TBD) is shown in white. (B) RNA encoding either XStau234 (DN, lanes 1, 3) or full-length XStau (WT, lane 2) was injected into stage III oocytes, and S10 lysates were prepared after 16 hour incubation. Expression of injected RNA was analyzed by immunoblotting with FLAG antibodies (lanes 1, 2); immunoblotting with XStau antibodies (lane 3) was used to compare expression of XStau234 (DN, below) to that of endogenous XStau (above). (C) Fluorescently labeled VLE RNA was injected into oocytes expressing either full-length XStau (WT, left) or XStau234 (DN, right). Examples are shown of the predominant phenotypes observed for oocytes expressing full-length XStau (WT), showing localization of VLE RNA (red) and XStau234 (DN), exhibiting no detectable localization. Scale bars: 100 µm. (D) Localization was scored for VLE-injected oocytes expressing either WT XStau (left, n=151) or DN XStau (right, n=117). The graph shows the percentage of oocytes that exhibited strong vegetal localization (green), weak vegetal localization (yellow) or no detectable localization (red). (E) S10 lysates were prepared from oocytes expressing either XStau234 (DN, lane 1) or full-length XStau (WT, lane 2), and immunoprecipitation was performed using FLAG antibodies. Bound proteins were separated by SDS-PAGE and immunoblotted with Vg1RBP/vera antibodies (above) and hnRNP I antibodies (below).





Right arrow Return to article